ACC CardiaCast: Emerging Data in SGLT2 Inhibitors

This podcast discusses new data pertaining to the class of SGLT2 inhibitors in the treatment of diabetes and its cardioprotective properties. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the results of the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial will help prepare you to better treat your patients.